donepezil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
946 120014-06-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aricept
  • donepezil
  • donepezil hydrochloride
  • donepezil HCl
  • donezpil hydrochloride
  • donezpil
  • donezpil HCl
  • donepezilium oxalate trihydrate
  • donepezilium oxalate
  • donepezil oxalate
  • E2020
  • E-2020
An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
  • Molecular weight: 379.50
  • Formula: C24H29NO3
  • CLOGP: 4.60
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 38.77
  • ALOGS: -4.93
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
7.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10.60 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.38 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Nov. 25, 1996 FDA EISAI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bradycardia 548.25 12.94 410 32886 70646 53245124
Fall 422.60 12.94 780 32516 357660 52958110
Dementia 312.15 12.94 169 33127 16581 53299189
Syncope 289.77 12.94 353 32943 111640 53204130
Electrocardiogram QT prolonged 281.91 12.94 253 33043 56150 53259620
Confusional state 237.13 12.94 430 32866 193791 53121979
Sinus bradycardia 232.87 12.94 133 33163 14468 53301302
Hallucination 207.07 12.94 209 33087 53629 53262141
Drug interaction 203.85 12.94 433 32863 218896 53096874
Torsade de pointes 187.61 12.94 111 33185 12894 53302876
Agitation 176.70 12.94 200 33096 58426 53257344
Cognitive disorder 165.19 12.94 170 33126 44608 53271162
Dementia Alzheimer's type 160.97 12.94 50 33246 1147 53314623
Delusion 156.42 12.94 96 33200 11913 53303857
Aggression 156.00 12.94 124 33172 23279 53292491
Abnormal behaviour 143.92 12.94 115 33181 21751 53294019
Delirium 139.80 12.94 150 33146 41279 53274491
Rheumatoid arthritis 133.41 12.94 19 33277 314512 53001258
Neuroleptic malignant syndrome 131.28 12.94 86 33210 11947 53303823
Parkinsonism 130.18 12.94 77 33219 8936 53306834
Drug ineffective 129.07 12.94 195 33101 817050 52498720
Pleurothotonus 118.29 12.94 41 33255 1338 53314432
Seizure 107.92 12.94 245 33051 129264 53186506
Arthralgia 105.41 12.94 73 33223 439710 52876060
Hallucination, visual 103.02 12.94 89 33207 18743 53297027
Somnolence 97.67 12.94 277 33019 167457 53148313
Cholinergic syndrome 90.74 12.94 25 33271 370 53315400
Sinus node dysfunction 89.65 12.94 47 33249 4314 53311456
Pain 88.24 12.94 145 33151 588253 52727517
Tremor 87.65 12.94 222 33074 125514 53190256
Loss of consciousness 86.31 12.94 208 33088 114004 53201766
Extrapyramidal disorder 85.40 12.94 67 33229 12335 53303435
Myoclonus 85.21 12.94 74 33222 15690 53300080
Alopecia 82.94 12.94 22 33274 234561 53081209
Altered state of consciousness 80.39 12.94 88 33208 24748 53291022
Electrocardiogram PR prolongation 80.00 12.94 26 33270 693 53315077
Femoral neck fracture 79.66 12.94 55 33241 8328 53307442
Muscle rigidity 77.75 12.94 60 33236 10781 53304989
Hypersensitivity 75.92 12.94 19 33277 210646 53105124
Decreased appetite 75.18 12.94 299 32997 214675 53101095
Depressed level of consciousness 74.58 12.94 127 33169 54301 53261469
Atrioventricular block first degree 74.45 12.94 48 33248 6487 53309283
Joint swelling 74.01 12.94 27 33269 234611 53081159
Dehydration 72.04 12.94 250 33046 168160 53147610
Hypothermia 72.01 12.94 62 33234 12994 53302776
Torticollis 71.21 12.94 31 33265 1879 53313891
Rash 70.54 12.94 106 33190 446085 52869685
Mental status changes 68.88 12.94 103 33193 39468 53276302
Immobile 66.11 12.94 41 33255 5179 53310591
Urinary retention 65.89 12.94 85 33211 28381 53287389
Mania 64.89 12.94 56 33240 11773 53303997
Treatment failure 64.24 12.94 4 33292 128399 53187371
Disorientation 63.64 12.94 99 33197 39260 53276510
Urinary incontinence 63.60 12.94 87 33209 30734 53285036
Hypokalaemia 62.68 12.94 166 33130 96351 53219419
Infusion related reaction 62.46 12.94 11 33285 155946 53159824
Systemic lupus erythematosus 59.60 12.94 5 33291 125409 53190361
Nightmare 59.37 12.94 64 33232 17687 53298083
Hypophagia 58.61 12.94 84 33212 30978 53284792
Sinusitis 57.34 12.94 17 33279 168547 53147223
Arthropathy 56.60 12.94 10 33286 141443 53174327
Lethargy 55.45 12.94 111 33185 53649 53262121
Urinary tract infection 54.42 12.94 294 33002 239609 53076161
Dyskinesia 52.76 12.94 81 33215 31752 53284018
Swelling 52.29 12.94 27 33269 191078 53124692
Pruritus 52.23 12.94 64 33232 293768 53022002
Sudden death 49.21 12.94 45 33251 10203 53305567
Drug hypersensitivity 49.03 12.94 56 33240 265186 53050584
Wandering pacemaker 48.49 12.94 8 33288 3 53315767
Unresponsive to stimuli 48.44 12.94 80 33216 33346 53282424
Gastrointestinal haemorrhage 46.02 12.94 132 33164 80198 53235572
Restlessness 45.89 12.94 71 33225 28016 53287754
Pain in extremity 45.66 12.94 67 33229 284983 53030787
Cerebral atrophy 45.60 12.94 32 33264 4972 53310798
Reduced facial expression 45.11 12.94 22 33274 1732 53314038
Glossodynia 45.01 12.94 5 33291 100286 53215484
Pemphigus 44.69 12.94 6 33290 104025 53211745
Psychomotor hyperactivity 43.99 12.94 42 33254 10054 53305716
Hypocapnia 43.33 12.94 14 33282 366 53315404
Circulatory collapse 42.23 12.94 61 33235 22653 53293117
Atrioventricular block complete 42.06 12.94 37 33259 7978 53307792
Generalised tonic-clonic seizure 41.90 12.94 69 33227 28689 53287081
Tardive dyskinesia 41.84 12.94 37 33259 8033 53307737
Drug intolerance 41.76 12.94 40 33256 205453 53110317
Encephalopathy 41.60 12.94 79 33217 36729 53279041
Anal incontinence 41.24 12.94 45 33251 12602 53303168
Apathy 40.89 12.94 37 33259 8275 53307495
Medication error 39.81 12.94 77 33219 36288 53279482
Cough 39.57 12.94 62 33234 256831 53058939
Hypersexuality 39.24 12.94 14 33282 498 53315272
Memory impairment 38.98 12.94 129 33167 84628 53231142
Sexually inappropriate behaviour 38.77 12.94 10 33286 113 53315657
Hip fracture 38.77 12.94 66 33230 28191 53287579
Febrile neutropenia 38.68 12.94 9 33287 104927 53210843
Headache 37.59 12.94 190 33106 536631 52779139
Lower respiratory tract infection 37.34 12.94 6 33290 90975 53224795
Off label use 37.26 12.94 160 33136 472052 52843718
Neuropsychiatric symptoms 36.39 12.94 14 33282 617 53315153
Pneumonia aspiration 35.57 12.94 71 33225 34230 53281540
Gait disturbance 35.52 12.94 194 33102 158648 53157122
Long QT syndrome 34.59 12.94 23 33273 3273 53312497
Miosis 34.12 12.94 31 33265 6971 53308799
Epilepsy 33.80 12.94 59 33237 25708 53290062
Psoriasis 33.04 12.94 7 33289 87082 53228688
Dementia with Lewy bodies 32.97 12.94 11 33285 319 53315451
Therapeutic product effect decreased 32.54 12.94 19 33277 125636 53190134
Listless 32.03 12.94 20 33276 2556 53313214
Weight increased 31.84 12.94 49 33247 204518 53111252
Atrioventricular block 31.67 12.94 30 33266 7110 53308660
Atrial tachycardia 31.64 12.94 19 33277 2265 53313505
Dyspnoea 31.30 12.94 226 33070 586006 52729764
Infection 31.10 12.94 37 33259 172168 53143602
Rhabdomyolysis 31.02 12.94 78 33218 43845 53271925
Lack of spontaneous speech 30.97 12.94 9 33287 163 53315607
Fatigue 30.73 12.94 300 32996 730206 52585564
Dizziness 30.68 12.94 361 32935 371898 52943872
Hyponatraemia 30.14 12.94 141 33155 108466 53207304
Parkinson's disease 30.05 12.94 16 33280 1515 53314255
Sinus arrest 29.93 12.94 17 33279 1827 53313943
Incontinence 29.56 12.94 35 33261 10708 53305062
Pericarditis 29.43 12.94 3 33293 64403 53251367
Product administration interrupted 29.43 12.94 13 33283 816 53314954
Paratonia 29.05 12.94 6 33290 22 53315748
Fluid intake reduced 28.88 12.94 21 33275 3448 53312322
Hypotension 28.80 12.94 263 33033 253813 53061957
Fracture 28.66 12.94 45 33251 17974 53297796
Stomatitis 28.14 12.94 13 33283 98145 53217625
Accidental overdose 27.94 12.94 49 33247 21430 53294340
Wrong patient received product 27.67 12.94 17 33279 2111 53313659
Dysarthria 27.56 12.94 71 33225 40497 53275273
Atrial fibrillation 27.43 12.94 140 33156 111512 53204258
Delusional disorder, persecutory type 27.22 12.94 8 33288 151 53315619
Nasopharyngitis 27.20 12.94 49 33247 192246 53123524
Hypernatraemia 26.56 12.94 27 33269 6970 53308800
Abdominal discomfort 26.46 12.94 62 33234 221000 53094770
Posture abnormal 26.17 12.94 17 33279 2326 53313444
Speech disorder 26.03 12.94 68 33228 39113 53276657
Overconfidence 25.52 12.94 4 33292 0 53315770
Cerebrovascular accident 25.23 12.94 131 33165 105043 53210727
Therapeutic product effect incomplete 25.03 12.94 13 33283 91771 53223999
Hyperhidrosis 24.93 12.94 123 33173 96670 53219100
Oropharyngeal pain 24.51 12.94 10 33286 81258 53234512
Grandiosity 24.28 12.94 8 33288 223 53315547
Pelvic fracture 24.15 12.94 34 33262 12330 53303440
Suspiciousness 24.10 12.94 9 33287 365 53315405
Cerebral haemorrhage 24.10 12.94 56 33240 29940 53285830
Product use issue 23.11 12.94 32 33264 139552 53176218
Colitis microscopic 22.71 12.94 25 33271 7069 53308701
Anger 22.63 12.94 33 33263 12357 53303413
Chorea 22.58 12.94 13 33283 1434 53314336
Ventricular tachycardia 22.43 12.94 40 33256 17722 53298048
Social avoidant behaviour 22.34 12.94 17 33279 2991 53312779
Bedridden 22.17 12.94 29 33267 9808 53305962
Drug level increased 22.05 12.94 43 33253 20378 53295392
Chest discomfort 21.93 12.94 18 33278 99677 53216093
Hepatic enzyme increased 21.84 12.94 28 33268 126167 53189603
Food refusal 21.67 12.94 8 33288 314 53315456
Incoherent 21.43 12.94 20 33276 4652 53311118
Salivary hypersecretion 21.42 12.94 24 33272 6919 53308851
Skull fracture 21.35 12.94 11 33285 974 53314796
Sedation 21.26 12.94 53 33243 29622 53286148
Hypertonia 21.20 12.94 20 33276 4717 53311053
Orthostatic hypotension 21.17 12.94 53 33243 29700 53286070
Impaired healing 20.88 12.94 7 33289 64198 53251572
Hypomania 20.68 12.94 20 33276 4862 53310908
Brain compression 20.47 12.94 8 33288 368 53315402
Psoriatic arthropathy 20.17 12.94 3 33293 48187 53267583
Psychotic disorder 20.11 12.94 46 33250 24339 53291431
Cerebral infarction 20.04 12.94 46 33250 24398 53291372
Drooling 20.04 12.94 17 33279 3491 53312279
Executive dysfunction 19.99 12.94 6 33290 122 53315648
Sinoatrial block 19.93 12.94 10 33286 837 53314933
Catatonia 19.91 12.94 18 33278 4022 53311748
Pyrexia 19.77 12.94 159 33137 403034 52912736
Urticaria 19.77 12.94 34 33262 135851 53179919
Vomiting 19.51 12.94 426 32870 496713 52819057
Inappropriate affect 19.47 12.94 10 33286 879 53314891
Hyponatraemic syndrome 19.36 12.94 9 33287 637 53315133
Adams-Stokes syndrome 19.35 12.94 5 33291 57 53315713
Peripheral swelling 19.33 12.94 65 33231 206043 53109727
Non-24-hour sleep-wake disorder 19.30 12.94 4 33292 15 53315755
Upper gastrointestinal haemorrhage 19.18 12.94 37 33259 17393 53298377
Normal pressure hydrocephalus 18.89 12.94 7 33289 278 53315492
Myalgia 18.88 12.94 34 33262 133457 53182313
Paranoia 18.82 12.94 29 33267 11395 53304375
Blood pressure orthostatic decreased 18.75 12.94 5 33291 65 53315705
Intentional product use issue 18.71 12.94 11 33285 72483 53243287
Antisocial behaviour 18.70 12.94 7 33289 286 53315484
Death 18.37 12.94 319 32977 356913 52958857
Injection site erythema 18.19 12.94 13 33283 77236 53238534
Muscle contracture 18.12 12.94 11 33285 1337 53314433
Foreign body 17.97 12.94 13 33283 2118 53313652
Anaphylactic reaction 17.87 12.94 7 33289 58319 53257451
Emotional poverty 17.87 12.94 7 33289 324 53315446
Herbal interaction 17.84 12.94 5 33291 79 53315691
Injection site pain 17.78 12.94 27 33269 113364 53202406
Obsessive thoughts 17.63 12.94 8 33288 535 53315235
Abnormal dreams 17.59 12.94 27 33269 10574 53305196
Prescription drug used without a prescription 17.58 12.94 12 33284 1782 53313988
Wound 17.24 12.94 19 33277 91538 53224232
Affect lability 17.16 12.94 25 33271 9350 53306420
Dyspepsia 17.07 12.94 14 33282 77586 53238184
Aphasia 17.06 12.94 50 33246 30728 53285042
Asthma 17.04 12.94 26 33270 108946 53206824
Leukaemoid reaction 17.02 12.94 6 33290 206 53315564
Pressure of speech 16.86 12.94 8 33288 593 53315177
Liver function test abnormal 16.85 12.94 67 33229 48004 53267766
Rash papulosquamous 16.79 12.94 5 33291 99 53315671
Anorgasmia 16.76 12.94 8 33288 601 53315169
Discomfort 16.71 12.94 21 33275 95451 53220319
Paraesthesia 16.70 12.94 34 33262 127481 53188289
Hypoglycaemia 16.64 12.94 77 33219 58936 53256834
Duodenal ulcer haemorrhage 16.31 12.94 13 33283 2447 53313323
Communication disorder 16.30 12.94 13 33283 2448 53313322
Disease progression 16.24 12.94 24 33272 101896 53213874
Intercepted product dispensing error 16.16 12.94 5 33291 113 53315657
Hypoaesthesia 16.14 12.94 37 33259 132958 53182812
Injection site reaction 15.91 12.94 6 33290 51160 53264610
Fibromyalgia 15.80 12.94 4 33292 44071 53271699
Neutropenia 15.75 12.94 49 33247 159136 53156634
Irritable bowel syndrome 15.57 12.94 4 33292 43628 53272142
Product use in unapproved indication 15.52 12.94 29 33267 112260 53203510
Product dispensing error 15.50 12.94 25 33271 10215 53305555
Arthritis 15.49 12.94 19 33277 87279 53228491
Drop attacks 15.17 12.94 8 33288 743 53315027
Haematoma 15.09 12.94 51 33245 33793 53281977
Erythema 15.06 12.94 49 33247 156920 53158850
Injection site swelling 15.03 12.94 4 33292 42624 53273146
Gastric ulcer 14.95 12.94 40 33256 23329 53292441
Dysphagia 14.93 12.94 97 33199 84300 53231470
Delusion of grandeur 14.79 12.94 5 33291 151 53315619
Gastric ulcer haemorrhage 14.72 12.94 17 33279 5065 53310705
Libido increased 14.69 12.94 9 33287 1112 53314658
Language disorder 14.63 12.94 11 33285 1900 53313870
Pemphigoid 14.53 12.94 19 33277 6425 53309345
Cholesteatoma 14.52 12.94 5 33291 160 53315610
Heart rate increased 14.51 12.94 18 33278 82297 53233473
Impaired self-care 14.51 12.94 11 33285 1924 53313846
Blood glucose fluctuation 14.50 12.94 16 33280 4535 53311235
Malignant neoplasm progression 14.43 12.94 14 33282 71527 53244243
Amnesia 14.21 12.94 61 33235 45227 53270543
Crying 14.14 12.94 38 33258 22224 53293546
Neuropathy peripheral 13.95 12.94 27 33269 103160 53212610
Opisthotonus 13.95 12.94 6 33290 353 53315417
Nasal congestion 13.87 12.94 8 33288 53279 53262491
Progressive supranuclear palsy 13.74 12.94 4 33292 73 53315697
Acute abdomen 13.72 12.94 10 33286 1648 53314122
Subdural haematoma 13.61 12.94 28 33268 13785 53301985
Muscle twitching 13.56 12.94 31 33265 16395 53299375
Visuospatial deficit 13.46 12.94 3 33293 17 53315753
Thalamus haemorrhage 13.46 12.94 7 33289 632 53315138
Hypoglycaemic coma 13.41 12.94 12 33284 2646 53313124
Product blister packaging issue 13.39 12.94 5 33291 203 53315567
Haematemesis 13.32 12.94 46 33250 30811 53284959
Bundle branch block left 13.27 12.94 19 33277 6994 53308776
Gait inability 13.11 12.94 53 33243 38258 53277512
Apraxia 13.10 12.94 10 33286 1768 53314002
Inflammation 12.96 12.94 10 33286 57126 53258644

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 379.43 14.39 313 23786 52306 32437121
Dementia 369.74 14.39 186 23913 13200 32476227
Fall 331.85 14.39 551 23548 195650 32293777
Bradycardia 311.46 14.39 321 23778 71241 32418186
Confusional state 271.67 14.39 424 23675 142691 32346736
Agitation 185.19 14.39 220 23879 57016 32432411
Delusion 184.10 14.39 117 23982 12991 32476436
Delirium 146.87 14.39 172 23927 43874 32445553
Aggression 136.65 14.39 157 23942 39232 32450195
Pleurothotonus 129.10 14.39 43 24056 1038 32488389
Abnormal behaviour 128.20 14.39 126 23973 26340 32463087
Cognitive disorder 126.78 14.39 124 23975 25770 32463657
Cholinergic syndrome 100.93 14.39 30 24069 492 32488935
Depressed level of consciousness 94.34 14.39 133 23966 40714 32448713
Hallucination, visual 93.12 14.39 87 24012 17072 32472355
Somnolence 85.36 14.39 217 23882 103580 32385847
Mania 83.58 14.39 64 24035 9568 32479859
Neuroleptic malignant syndrome 82.30 14.39 82 24017 17413 32472014
Syncope 78.90 14.39 193 23906 89931 32399496
Urinary incontinence 74.19 14.39 79 24020 18128 32471299
Sinus node dysfunction 69.28 14.39 41 24058 4003 32485424
Sinus bradycardia 69.04 14.39 65 24034 12873 32476554
Dementia Alzheimer's type 66.61 14.39 21 24078 423 32489004
Gait disturbance 61.83 14.39 164 23935 80244 32409183
Memory impairment 61.75 14.39 109 23990 40370 32449057
Febrile neutropenia 61.52 14.39 8 24091 119558 32369869
Balance disorder 59.86 14.39 106 23993 39353 32450074
Nightmare 58.78 14.39 60 24039 13106 32476321
Blood cholinesterase decreased 55.28 14.39 14 24085 121 32489306
Serotonin syndrome 49.77 14.39 66 24033 19051 32470376
Pneumonia aspiration 45.81 14.39 97 24002 41059 32448368
Parkinsonism 44.81 14.39 41 24058 7828 32481599
Neutropenia 44.55 14.39 25 24074 142150 32347277
Unresponsive to stimuli 44.25 14.39 76 24023 27533 32461894
Tremor 43.64 14.39 146 23953 81131 32408296
Prescribed underdose 41.48 14.39 41 24058 8618 32480809
Poriomania 41.05 14.39 11 24088 121 32489306
Extrapyramidal disorder 40.50 14.39 47 24052 11848 32477579
Loss of consciousness 40.42 14.39 144 23955 82563 32406864
Orthostatic hypotension 40.31 14.39 70 24029 25580 32463847
Death 39.67 14.39 445 23654 382072 32107355
Libido increased 39.37 14.39 17 24082 848 32488579
Hyperhidrosis 39.23 14.39 129 23970 71039 32418388
Myoclonus 38.84 14.39 51 24048 14578 32474849
Disorientation 37.45 14.39 79 24020 33346 32456081
Anal incontinence 35.96 14.39 35 24064 7219 32482208
Dyskinesia 35.26 14.39 63 24036 23540 32465887
Arthralgia 35.06 14.39 35 24064 148413 32341014
Automatism 34.18 14.39 9 24090 92 32489335
Jealous delusion 33.08 14.39 11 24088 264 32489163
Restlessness 32.88 14.39 63 24036 24818 32464609
Paranoia 32.38 14.39 40 24059 10759 32478668
Mental status changes 32.32 14.39 81 24018 38256 32451171
Hypersomnia 32.22 14.39 42 24057 11919 32477508
Rhabdomyolysis 31.90 14.39 116 23983 67149 32422278
Somatic delusion 31.59 14.39 9 24090 126 32489301
Dizziness 31.58 14.39 264 23835 209354 32280073
Lethargy 31.56 14.39 84 24015 41144 32448283
Product prescribing issue 31.45 14.39 16 24083 1159 32488268
Blood glucose fluctuation 31.23 14.39 25 24074 3984 32485443
Salivary hypersecretion 31.02 14.39 34 24065 8054 32481373
Intestinal haemorrhage 30.51 14.39 23 24076 3356 32486071
Dyspnoea 29.66 14.39 153 23946 361892 32127535
Bradyarrhythmia 29.66 14.39 19 24080 2135 32487292
Parkinson's disease 28.26 14.39 17 24082 1709 32487718
Abdominal pain 28.18 14.39 42 24057 149487 32339940
Sexually inappropriate behaviour 27.46 14.39 11 24088 453 32488974
Nonspecific reaction 26.80 14.39 15 24084 1317 32488110
Drooling 26.62 14.39 21 24078 3276 32486151
Electrocardiogram QT prolonged 26.61 14.39 77 24022 39564 32449863
Hypothermia 26.47 14.39 35 24064 10068 32479359
Dementia with Lewy bodies 26.45 14.39 12 24087 674 32488753
Psychomotor hyperactivity 26.33 14.39 33 24066 9006 32480421
Flight of ideas 26.19 14.39 10 24089 362 32489065
Dysstasia 25.89 14.39 37 24062 11449 32477978
Thrombocytopenia 25.73 14.39 44 24055 148255 32341172
Miosis 25.71 14.39 32 24067 8672 32480755
Drug abuse 25.27 14.39 14 24085 80229 32409198
Seizure 25.18 14.39 147 23952 103707 32385720
Muscle rigidity 25.17 14.39 36 24063 11150 32478277
Hip fracture 24.95 14.39 37 24062 11838 32477589
Drug interaction 24.90 14.39 259 23840 217926 32271501
Neuropathy peripheral 24.87 14.39 13 24086 76969 32412458
Gastrointestinal haemorrhage 24.41 14.39 128 23971 86754 32402673
Muscle contractions involuntary 24.08 14.39 16 24083 1912 32487515
Altered state of consciousness 23.49 14.39 51 24048 21946 32467481
Atrioventricular block complete 23.46 14.39 31 24068 8913 32480514
Contusion 23.43 14.39 66 24033 33402 32456025
Pain 23.22 14.39 67 24032 187489 32301938
Gait inability 23.17 14.39 48 24051 19999 32469428
Dehydration 23.01 14.39 169 23930 128789 32360638
Cerebral atrophy 22.73 14.39 22 24077 4505 32484922
Neutrophil count decreased 22.29 14.39 4 24095 47135 32442292
Irritability 21.74 14.39 53 24046 24601 32464826
Daydreaming 21.72 14.39 10 24089 581 32488846
Inappropriate antidiuretic hormone secretion 21.72 14.39 35 24064 12028 32477399
Skin swelling 21.67 14.39 12 24087 1032 32488395
Atrioventricular block first degree 21.57 14.39 24 24075 5779 32483648
Hangover 21.10 14.39 12 24087 1087 32488340
Femoral neck fracture 21.07 14.39 18 24081 3138 32486289
Cold sweat 20.91 14.39 31 24068 9915 32479512
Pruritus 20.69 14.39 40 24059 128662 32360765
Blood glucose abnormal 20.58 14.39 23 24076 5565 32483862
Gastrointestinal ulcer 20.37 14.39 14 24085 1769 32487658
Septic shock 20.36 14.39 13 24086 68976 32420451
Malignant neoplasm progression 20.30 14.39 17 24082 78479 32410948
Subdural haematoma 19.88 14.39 45 24054 19908 32469519
Executive dysfunction 19.86 14.39 7 24092 201 32489226
Multiple organ dysfunction syndrome 19.50 14.39 14 24085 69840 32419587
Intention tremor 19.30 14.39 8 24091 360 32489067
Defect conduction intraventricular 19.27 14.39 7 24092 220 32489207
Paraesthesia 18.97 14.39 10 24089 58934 32430493
Speech disorder 18.59 14.39 52 24047 26201 32463226
Urinary tract infection 18.53 14.39 112 23987 79959 32409468
Gastroenteritis pseudomonas 18.41 14.39 4 24095 16 32489411
Duodenal ulcer 18.37 14.39 30 24069 10425 32479002
Decreased appetite 18.36 14.39 191 23908 160622 32328805
Hiccups 18.21 14.39 29 24070 9866 32479561
Posture abnormal 17.77 14.39 14 24085 2179 32487248
Potentiating drug interaction 17.40 14.39 20 24079 4988 32484439
Behaviour disorder 17.06 14.39 17 24082 3607 32485820
Condition aggravated 16.89 14.39 183 23916 155478 32333949
Leukopenia 16.84 14.39 12 24087 60110 32429317
Rheumatoid arthritis 16.80 14.39 6 24093 44538 32444889
Atrioventricular block 16.29 14.39 24 24075 7631 32481796
Foaming at mouth 16.02 14.39 9 24090 796 32488631
Underdose 15.94 14.39 32 24067 13037 32476390
Multiple drug therapy 15.88 14.39 7 24092 367 32489060
Tardive dyskinesia 15.80 14.39 20 24079 5511 32483916
Impulsive behaviour 15.68 14.39 13 24086 2176 32487251
Incontinence 15.53 14.39 20 24079 5606 32483821
Drug hypersensitivity 15.44 14.39 19 24080 73381 32416046
Urticaria 15.30 14.39 13 24086 59601 32429826
Post-traumatic stress disorder 15.28 14.39 12 24087 1859 32487568
Pyrexia 15.12 14.39 158 23941 319810 32169617
Loss of personal independence in daily activities 15.09 14.39 49 24050 26784 32462643
Hypernatraemia 14.97 14.39 24 24075 8209 32481218
Hypomania 14.60 14.39 13 24086 2396 32487031
Musculoskeletal pain 14.46 14.39 3 24096 31894 32457533
Frontotemporal dementia 14.39 14.39 6 24093 274 32489153

Pharmacologic Action:

SourceCodeDescription
ATC N06DA02 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
ATC N06DA52 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
ATC N06DA53 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
FDA MoA N0000000177 Cholinesterase Inhibitors
CHEBI has role CHEBI:38462 acetylcholine esterase inhibitor
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D002800 Cholinesterase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018697 Nootropic Agents
FDA EPC N0000175723 Cholinesterase Inhibitor
CHEBI has role CHEBI:37733 BChE inhibitor
CHEBI has role CHEBI:66980 nootropics

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Alzheimer's disease indication 26929004 DOID:10652
Moderate to Severe Alzheimer's Type Dementia indication
Diffuse Lewy body disease off-label use 80098002
Sick sinus syndrome contraindication 36083008 DOID:13884
Gastrointestinal ulcer contraindication 40845000
Sinus bradycardia contraindication 49710005
Gastrointestinal hemorrhage contraindication 74474003
Epilepsy contraindication 84757009 DOID:1826
Asthma contraindication 195967001 DOID:2841
Atrioventricular block contraindication 233917008 DOID:0050820
Bladder outflow obstruction contraindication 236645006
NSAID-Induced Gastric Ulcer contraindication
Chronic Obstructive Pulmonary Disease with Bronchospasms contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.4 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG;14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8338486 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8580858 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8338486 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8580858 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8338486 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8580858 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8173708 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8283379 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8338486 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8362085 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8580858 Nov. 22, 2025 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8039009 March 24, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG NAMZARIC ALLERGAN N206439 Dec. 23, 2014 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG NAMZARIC ALLERGAN N206439 July 18, 2016 RX CAPSULE, EXTENDED RELEASE ORAL 8058291 Dec. 5, 2029 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Acetylcholinesterase Enzyme INHIBITOR Ki 7.80 WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.70 CHEMBL
Multidrug resistance protein 1 Transporter IC50 4.46 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 5.05 WOMBAT-PK
Amine oxidase [flavin-containing] B Enzyme IC50 4.82 CHEMBL
Cholinesterase Enzyme Ki 4.90 CHEMBL
Histamine H3 receptor GPCR IC50 6.46 CHEMBL
Beta-secretase 1 Enzyme IC50 5.49 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.84 CHEMBL
Acetylcholinesterase Enzyme IC50 8.24 CHEMBL
Acetylcholinesterase Enzyme IC50 8.24 CHEMBL
Butyrylcholinesterase; Protein Bche Enzyme IC50 5.56 CHEMBL
Acetylcholinesterase Enzyme IC50 8.77 CHEMBL
Acetylcholinesterase Enzyme Ki 7.25 CHEMBL
Acetylcholinesterase Enzyme Ki 8.54 CHEMBL
Choline O-acetyltransferase Enzyme IC50 8.28 CHEMBL
Amine oxidase [flavin-containing] B Enzyme IC50 4.82 CHEMBL
Cholinesterase Enzyme IC50 5.15 CHEMBL
Butyrylcholinesterase Enzyme Ki 6.19 CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane other Ki 7.84 CHEMBL
Cholinesterase Enzyme IC50 6.08 CHEMBL

External reference:

IDSource
D00670 KEGG_DRUG
120011-70-3 SECONDARY_CAS_RN
4021006 VANDF
4024045 VANDF
C0527316 UMLSCUI
CHEBI:53289 CHEBI
E20 PDB_CHEM_ID
CHEMBL502 ChEMBL_ID
CHEMBL1678 ChEMBL_ID
DB00843 DRUGBANK_ID
D000077265 MESH_DESCRIPTOR_UI
3152 PUBCHEM_CID
6599 IUPHAR_LIGAND_ID
7517 INN_ID
8SSC91326P UNII
135446 RXNORM
15004 MMSL
178540 MMSL
4631 MMSL
6432 MMSL
d04099 MMSL
006295 NDDF
006296 NDDF
108497001 SNOMEDCT_US
386855006 SNOMEDCT_US
386856007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Donepezil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9747 TABLET, FILM COATED 5 mg ORAL ANDA 24 sections
Donepezil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9748 TABLET, FILM COATED 10 mg ORAL ANDA 24 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1207 CAPSULE 10 mg ORAL NDA 31 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1214 CAPSULE 10 mg ORAL NDA 31 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1221 CAPSULE 10 mg ORAL NDA 31 sections
Namzaric HUMAN PRESCRIPTION DRUG LABEL 2 0456-1228 CAPSULE 10 mg ORAL NDA 31 sections
Donepezil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7951 TABLET, FILM COATED 5 mg ORAL ANDA 18 sections
Donepezil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7952 TABLET, FILM COATED 10 mg ORAL ANDA 18 sections
Donepezil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8313 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
Donepezil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5276 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 26 sections
Donepezil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-5277 TABLET, ORALLY DISINTEGRATING 10 mg ORAL ANDA 26 sections
Donepezil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6477 TABLET, FILM COATED 5 mg ORAL ANDA 24 sections
Donepezil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6478 TABLET, FILM COATED 10 mg ORAL ANDA 24 sections
Donepezil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-102 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Donepezil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-103 TABLET, FILM COATED 10 mg ORAL ANDA 25 sections
Donepezil Hydrochloride Human Prescription Drug Label 1 16571-778 TABLET, FILM COATED 5 mg ORAL ANDA 26 sections
Donepezil Hydrochloride Human Prescription Drug Label 1 16571-779 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
DONEPEZIL HYDROCHLORIDE Human Prescription Drug Label 1 24724-028 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
DONEPEZIL HYDROCHLORIDE Human Prescription Drug Label 1 24724-029 TABLET, FILM COATED 10 mg ORAL ANDA 25 sections
Donepezil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24979-004 TABLET, FILM COATED 23 mg ORAL ANDA 16 sections
donepezil hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-248 TABLET, FILM COATED 5 mg ORAL ANDA 23 sections
donepezil hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-249 TABLET, FILM COATED 10 mg ORAL ANDA 23 sections
donepezil hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-250 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 23 sections
donepezil hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 29300-251 TABLET, ORALLY DISINTEGRATING 10 mg ORAL ANDA 23 sections
Donepezil hydrochloride Human Prescription Drug Label 1 31722-139 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Donepezil hydrochloride Human Prescription Drug Label 1 31722-140 TABLET, FILM COATED 10 mg ORAL ANDA 25 sections
Donepezil Human Prescription Drug Label 1 31722-737 TABLET 5 mg ORAL ANDA 19 sections
Donepezil Human Prescription Drug Label 1 31722-738 TABLET 10 mg ORAL ANDA 19 sections
Donepezil Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-817 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
Donepezil Hydrochloride Human Prescription Drug Label 1 33342-027 TABLET, FILM COATED 5 mg ORAL ANDA 18 sections